ViiV HEALTHCARE TO ANNOUNCE DATA FROM LARGEST HEAD-TO-HEAD RANDOMISED CLINICAL TRIAL FOR 2-DRUG REGIMEN DOVATO AGAINST 3-DRUG REGIMEN BIKTARVY AT AIDS 2024
- Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato (dolutegravir/lamivudine) or Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Additional key abstracts from ViiV Healthcare’s industry-leading, long-acting pipeline and portfolio include data introducing a third-generation integrase strand transfer inhibitor (INSTI) with potential for ultra long-acting applications; pregnancy data for Apretude (cabotegravir long-acting injectable) for PrEP; and real-world evidence for long-acting treatment regimen Cabenuva (cabotegravir + rilpivirine long-acting)
London, 15 July 2024 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced it will be presenting the largest head-to-head, randomised clinical trial (RCT) of the 2-drug regimen Dovato (dolutegravir/lamivudine [DTG/3TC]) compared against the 3-drug regimen, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]) at the 25th International AIDS Conference in Munich, Germany (22 – 26 July). The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options alongside its next-generation pipeline assets.
Harmony P. Garges, M.D., Chief Medical Officer at ViiV Healthcare, said: “The exciting findings we’ll be presenting at AIDS 2024 continue to underscore our position as industry leaders in the development of long-acting and 2-drug regimens and our pioneering approaches to both HIV treatment and prevention. People living with HIV continue to tell us they want more treatment options to allow for more personal choice to address needs beyond viral suppression. The breadth of the data we’re announcing, including the head-to-head study between Dovato and Biktarvy, helps individuals better understand those options. We’re proud to be at the forefront of innovative science, driving advancements that have and will continue to transform the future of HIV care and contribute to ending the epidemic.”
Key abstracts to be presented at AIDS 2024 by ViiV Healthcare and its study partners will include:
Head-to-head study comparing ViiV Healthcare’s oral 2-drug regimen against a commonly prescribed oral 3-drug regimen: The FSG-sponsored PASO-DOBLE head-to-head RCT of the 2-drug regimen Dovato (DTG/3TC) compared with the 3-drug regimen Biktarvy (BIC/FTC/TAF) will be presented as a late breaker abstract. The non-inferiority study assessed virologically suppressed adults on an established treatment regimen and who could benefit from treatment optimisation, who were randomised to switch to treatment with DTG/3TC or BIC/FTC/TAF. Researchers will share 48-week findings on treatment efficacy and safety, as well as changes in weight experienced by participants while taking either regimen.1
Additional findings for DTG/3TC will include the DYAD study, presenting 48-week findings among virologically suppressed participants with no prior virologic failure who either switched to DTG/3TC or remained on BIC/FTC/TAF;2 and 96-week findings from the SOUND study, which followed virologically suppressed participants with unknown resistance history who switched from BIC/FTC/TAF to DTG/3TC.3
Pregnancy data from the HPTN 084 open label extension study for Apretude: New findings will be presented from the HPTN 084 trial that assess the impact of cabotegravir long-acting (LA) for PrEP exposure during pregnancy.4,5 The study focuses on maternal, pregnancy, and infant safety outcomes among participants who became pregnant during the open label extension of HPTN 084 and continued with injections of cabotegravir LA for PrEP.
New pipeline data from ViiV Healthcare’s third generation INSTI: Researchers will share phase I findings from the first-time-in-human study of VH184, a third-generation integrase inhibitor (INSTI), along with analysis showing potent activity in vitro against multiple INSTI resistant mutations.6 This is the first data presentation of the company’s next INSTI as a part of its ultra long-acting development strategy.
Real-world evidence from long-acting treatment regimen: Findings from several real-world studies of the complete long-acting HIV treatment regimen cabotegravir + rilpivirine long-acting (CAB+RPV LA) will be presented, including the perspectives of people living with HIV 12 months after switching their treatment regimen to CAB+RPV LA from the BEYOND study; 7,8 effectiveness, participant adherence to injections, and patient reported outcomes from the German cohort of the CARLOS study;9 and utilisation and effectiveness of CAB+RPV LA among virologically suppressed, treatment-experienced individuals from the COMBINE-2 study.10
Here is a list of ViiV Healthcare-sponsored or supported studies to be presented at AIDS 2024:
| Title | First author | Presentation number | Presentation |
| Dolutegravir/3TC |
|||
| Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASODOBLE (GeSIDA 11720) randomized clinical trial | P. Ryan | OAB3606LB | Oral Date of presentation: Friday, 26 July Session time: 12:00-13:00 CEST |
| PAIRED - Patient reported experiences and perceived benefit of treatment with dolutegravir/lamivudine - qualitative interviews: diverse group of people with HIV-1 (PWH) reflect on life and health |
J. Slim |
THPEB094 |
Poster Date of presentation: Thursday, 25 July Time of presentation: |
| Real-world effectiveness and tolerability of the 2-drug regimen dolutegravir and lamivudine (DTG/3TC) in people living with HIV: a systematic literature review and meta-analysis from clinical practice | J. Fraysse |
TUPEB101 |
Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Effectiveness and durability of dolutegravir/lamivudine in older people with HIV from the Veterans Aging Cohort Study (VACS) | L. Yan | WEPEB111 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study | J. Slim | THPEB092 | Poster Date of presentation: Thursday, 25 July Time of presentation: |
| Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide - 48-week results from the DYAD study | C. Rolle | THPEB089 | Poster Date of presentation: Thursday, 25 July Time of presentation: |
| Dolutegravir |
|||
| Viral suppression, viral failure and safety outcomes in children and adolescents on dolutegravir (DTG) in Europe and Thailand | K. Scott | OAB3803 | Oral Session date: Session time: |
| Changes in body mass index in children and adolescents in Europe and Thailand before and after starting dolutegravir and compared to protease inhibitors using propensity scoring analysis | S. Crichton | TUPEB086 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Prenatal dolutegravir-based regimen use, and pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry | V. Vannappagari | TUPEB128 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Effectiveness and durability of dolutegravir/ rilpivirine in older people with HIV from the Veterans Aging Cohort Study (VACS) | L. Yan | THPEB090 | Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Cabotegravir for treatment | |||
| Subcutaneous injections of cabotegravir + rilpivirine in virally suppressed adults with HIV-1: a substudy of the phase 3 FLAIR study | R. D’Amico | OAB2604 | Oral Session date: Thursday, 25 July 2024 Session time: |
| Clinical outcomes at month 12 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND) | S. Schneider | THPEB099 | Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) | W. Valenti | TUPEB116 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| 12-Month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort | C. Jonsson-Oldenbüttel | TBUPEB095 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Increased screening for sexually transmitted infections and HIV surrogate marker testing among long-acting injectable versus daily oral antiretroviral therapy users in the OPERA® cohort | P. C. Lackey | WEPEC319 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 cohort study | A. Pozniak |
TUPEC278 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Re-thinking ‘community’ in the implementation of long-acting injectable cabotegravir and rilpivirine: qualitative findings from the ILANA study | R. Hayes | TUPEE529 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| Adherence through the prism of long-acting injectable therapy: qualitative findings from the ILANA implementation study | S. Paparini | TUPED306 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| “Closer to a cure:” mixed-methods analysis of reasons for switching to cabotegravir + rilpivirine | S. Paparini | WEPEE551 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Cabotegravir for PrEP | |||
| “The simplest way to go:” A mixed methods analysis of why women who inject drugs selected long-acting injectable cabotegravir instead of daily oral PrEP | A. M. Roth | OAD07 | Oral Session date: Session time: |
| Knowledge, awareness, feasibility, and acceptability of long-acting cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial | E. Kakande | OAE12 | Oral Session date: Wednesday, 24 July Session time: |
| Location preferences for accessing long-acting injectable pre-exposure prophylaxis (LA-PrEP) among men who have sex with men (MSM) in the US currently using daily-oral PrEP | J. L. Glick |
WEPEC269 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| HIV pre-exposure prophylaxis awareness, willingness, and use among transfeminine persons with high likelihood of HIV in the United States: recent results from the Transgender Women’s Internet Survey and Testing (TWIST) | D. I. Yaras | THPEC186 | Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Preference for long-acting HIV prevention methods among transgender women at greatest risk for HIV acquisition in eastern and southern United States: findings from the LITE cohort | E. E. Cooney | THPED410 | Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Influencers and decision-making factors for choosing injectable PrEP among men who have sex with men and transgender men in the United States | D. Dandachi | THPEE504 |
Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Need for increased HIV testing prior to and during pre-exposure prophylaxis with cabotegravir long-acting injections in routine clinical care in the United States | R. K. Hsu | WEPEB046 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Pre-exposure prophylaxis (PrEP) product choice of participants in HPTN 083 | M. E. Clement | TUPEC184 | Poster Date of presentation: Tuesday, 23 July Time of presentation: 12:00-13:00 CEST |
| “Everyone should have access to it”: Perspectives on PrEP product choice and implementation from MSM and TGW in an injectable PrEP trial | C. Psaros | WEPEC206 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Pipeline | |||
| Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile | L. Rogg | OAB26 | Oral Session date: Thursday, 25 July Session time: |
| Preclinical assessments of a cabotegravir prodrug predicting human dosing durations of >6 months | M. Baker | WEPEA028 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Pre-clinical profiles of HIV-1 capsid inhibitors VH4004280 (VH-280) and VH4011499 (VH-499) | C. Wang | WEPEA027 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Clinical pharmacokinetics and safety of orally administered VH4004280 (VH-280), a novel HIV-1 capsid inhibitor, in healthy volunteers | R. Griesel | THPEB093 | Poster Date of presentation: Thursday, 25 July Time of presentation: 12:00-13:00 CEST |
| Clinical pharmacokinetics and safety of orally administered VH4011499 (VH-499), a novel HIV-1 capsid inhibitor, in healthy volunteers | N. Thakkar | WEPEB105 | Poster Date of presentation: Wednesday, 24 July Time of presentation: 12:00-13:00 CEST |
| Above Brand | |||
| Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV | O. Elvstam | OAB34 | Oral Session date: Friday, 26 July 2024 Session time: |
About Dovato
Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.
Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets.
About Vocabria
Vocabria (cabotegravir) injection is indicated - in combination with rilpivirine injection - , for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class.
Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:
- oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection.
- oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection.
Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant tablets should also be consulted for recommended dosing.
Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets
About Rekambys
Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV- 1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.
Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection).
Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection
About Apretude
Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir.
Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment please visit viivhealthcare.com.
About SEIMC-GeSIDA Foundation (FSG)
The SEIMC-GeSIDA Foundation (FSG) was founded by the Spanish Society of Clinical Microbiology and Infectious Diseases as a tool to promote high-quality investigation in the field of HIV infection and other infectious diseases. The Foundation is composed of qualified professionals with experience in the field of clinical trials and multicentre studies. Its streamlined infrastructure facilitates performance of clinical studies and responds to the needs of investigators in terms of methodology/statistical analysis and of logistics and management of trials and other multicentre studies. For more information on the SEIMC-GeSIDA Foundation (FSG), please visit https://fundacionseimcgesida.org/en/quienes-somos/
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
| ViiV Healthcare enquiries: | |||
| Media enquiries: | Rachel Jaikaran | +44 (0) 78 2352 3755 | (London) |
| Melinda Stubbee | +1 919 491 0831 | (North Carolina) | |
| Audrey Abernathy | +1 919 605 4521 | (North Carolina) | |
| FSG enquiries: | |||
| Media enquiries: | Tomas Muriel | +34 605 603 382 | (Spain) |
| Manuela Hernández | +34 651 867 278 | (Spain) | |
| GSK enquiries: | |||
| Media enquiries: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| Sarah Clements | +44 (0) 20 8047 5502 |
(London) | |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
| Lyndsay Meyer | +1 202 302 4595 | (Washington DC) | |
| Alison Hunt | +1 540 742 3391 | (Washington DC) | |
| Investor Relations: | Nick Stone | +44 (0) 7717 618834 | (London) |
| James Dodwell | +44 (0) 20 8047 2406 | (London) | |
| Mick Readey | +44 (0) 7990 339653 | (London) | |
| Josh Williams | +44 (0) 7385 415719 | (London) | |
| Camilla Campbell | +44 (0) 7803 050238 | (London) | |
| Steph Mountifield | +44 (0) 7796 707505 | (London) | |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
| Frannie DeFranco | +1 215 751 4855 | (Philadelphia) | |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q1 Results for 2024.
Registered in England & Wales:
GSK plc ViiV Healthcare Limited
No. 3888792 No. 06876960
Registered Office:
GSK plc ViiV Healthcare Limited
980 Great West Road GSK Medicines Research Centre
Brentford, Middlesex Gunnels Wood Road, Stevenage
United Kingdom United Kingdom
TW8 9GS SG1 2NY
References:
- P. Ryan, et al. Non-inferior efficacy and less weight gain when switching to DTG/3TC than when switching to BIC/FTC/TAF in virologically suppressed people with HIV (PWH): the PASODOBLE (GeSIDA 11720) randomized clinical trial. Presented at the 25th International AIDS Conference. July 2024.
- C.P. Rolle, et al. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide - 48-week results from the DYAD study. Presented at the 25th International AIDS Conference. July 2024.
- J. Slim, et al. Switch to dolutegravir/lamivudine (DTG/3TC) in people living with HIV-1 suppressed on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): 96-week final analysis from the SOUND study. Presented at the 25th International AIDS Conference. July 2024.
- S. Delany-Moretlwe, et al. Initial evaluation of CAB-LA Safety during pregnancy in the HPTN 084 open-label extension. Presented at the 25th International AIDS Conference. July 2024.
- M. Marzinke, et al. Evaluation of Long-Acting Cabotegravir (CAB-LA) Pharmacokinetics During Pregnancy: A Sub-Study Analysis of the HPTN 084 Open Label Extension. Presented at the 25th International AIDS Conference. July 2024.
- L. Rogg, et al. Phase 1 study of VH4524184 (VH-184), a new third-generation integrase strand transfer inhibitor (INSTI) with a unique resistance profile. Presented at the 25th International AIDS Conference. July 2024.
- S. Schneider, et al. Clinical outcomes at Month 12 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the 25th International AIDS Conference. July 2024.
- W. Valenti, et al. Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Presented at the 25th International AIDS Conference. July 2024.
- CJ. Oldenbüttel, et al. 12-Month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort. Presented at the 25th International AIDS Conference. July 2024.
- A. Pozniak, et al. Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 cohort study. Presented at the 25th International AIDS Conference. July 2024.
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries, email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
